AFMD: affimed.com Company Value to Net Income

Affimed Therapeutics - graphic logo of issuer AFMD

Serving as a valuation tool, the Affimed (AFMD) price chart demonstrates a P/E multiple of 0.00, with the business generating revenue from the development of anti-tumor agents and licensing royalties for access to ROCK technology. The firm's environmental policy focuses on modernizing treatment systems and conserving water resources within its laboratories. A competitive advantage is secured through exclusive patents for bispecific antibodies and a strategic alliance with the market's largest behemoths.

affimed.com (AFMD) Price to Earnings Ratio: for the period 07/04/2022 - 05/24/2025

Analytical breakdowns for Affimed NV (AFMD)

- price and consensus price forecast:
Stock Price Affimed Therapeutics|AFMD - Consensus Target
- market capitalization information:
Market Value Affimed N.V.|AFMD - Enterprise Value
- balance sheet net asset value indicators:
Net Assets per Share Affimed|AFMD - Company Book Value|Market Cap to Net Assets Ratio affimed.com|AFMD - Aggregate Company Assets
- debt and solvency information:
Total Debt to Equity Ratio Affimed|AFMD - Long-Term Debt to Equity Ratio|Short-Term Debt to Capital Affimed Therapeutics|AFMD - Company Debts|Debt to Book Value Ratio Affimed N.V.|AFMD - Company Long-Term Debts|Short-Term Debt Affimed|Quick Ratio affimed.com
- earnings and market multiples details:
AFMD - Net Profit|Forward Earnings Affimed|AFMD - P/E Multiple|Price to Expected Earnings Ratio Affimed Therapeutics|AFMD - PEG Multiple|Total Company Value to Operating Income Before Depreciation Ratio Affimed N.V.|AFMD - Profit before payment of interest, taxes and amortization|Net earnings per share for the last 12 months Affimed|AFMD - Net earnings per share (EPS TTM)|Earnings per share growth in annualized terms for the last twelve months affimed.com|AFMD - Earnings growth in current year|Projected earnings per share growth rate for next year Affimed
Comprehensive company analysis:affimed.com AFMD
Signature product of Affimed NV

Affimed is an oncology biotech whose viability relies on external financing and grants in the absence of its own sales. The P/E ratio relates current market capitalization to net profit, measuring the payback period for investments. This indicator allows for an assessment of market expectations regarding the future profitability of the business. Abnormal values signal either inflated hopes or a deep profit deficit. By analyzing the price-to-earnings ratio trend, an investor can see the real cost of each unit of income.

Key competitors

P/E Multiple argenx.com|Price to Earnings Ratio BNTX (BioNTech)|ABVX (ABIVAX) - Company Value to Net Income|P/E Multiple ADMA (ADMA Bio)|Business Payback Period Protagonist Corp (PTGX)|IMVT - Price to Earnings Ratio|kiniksa.com (KNSA) - Price to Earnings Ratio|Grifols (GRFS) - Price to Earnings Ratio|Price to Earnings Ratio Adaptive Biotech|Price to Earnings Ratio CLDX|P/E Multiple Aurinia Corp|Price to Earnings Ratio BioCryst (BCRX)|veratx.com - Price to Earnings Multiple|P/E Multiple DNTH (Dianthus Therapeutics, Inc.)|Pharvaris NV (PHVS) - Market Cap to Earnings|AbCellera Bio - P/E Multiple|TRML - P/E Multiple|PGEN: P/E Multiple|Market Cap to Net Income PHAR (pharming.com)|NKTR (Nektar Therapeutics Inc.) - P/E Multiple|Upstream Bio, Inc. - Market Cap to Net Income|P/E Multiple ZBIO|Business Payback Period Immunome Bio|Price to Earnings Ratio Gossamer Bio, Inc. GOSS|KALV - Price to Earnings Ratio|Septerna - P/E Multiple|Market Cap to Earnings Pieris Pharma|SVRA: P/E Multiple|Price to Earnings Multiple RIGL|ANAB (AnaptysBio, Inc.) - P/E Multiple|P/E Multiple astriatx.com|P/E Multiple ENGN|RAPT: Market Cap to Net Income|Price to Earnings Ratio Aerovate Therapeutics JBIO|ACRS - Price to Earnings Ratio|Kyverna Therapeutics - P/E Multiple|TLSA (tizianalifesciences.com) - Price to Earnings Multiple|Cabaletta Bio (CABA) - Price to Earnings Ratio|Market Cap to Net Income VTYX (Ventyx Biosciences Inc.)|THTX (Theratechnologies Inc) - P/E Multiple|AVTX: Company Value to Net Income|P/E Multiple ELDN|P/E Multiple agenusbio.com (AGEN)|Price to Earnings Ratio Climb Bio CLYM|Company Value to Net Income ZURA|ATYR - Price to Earnings Ratio|Adagene (ADAG) - Price to Earnings Ratio|IMA: P/E Multiple|Shattuck Labs (STTK) - P/E Multiple|Price to Earnings Ratio EQ|CNTB: Company Value to Net Income|P/E Multiple IMUX|Business Payback Period atarabio.com|Price to Earnings Ratio InflaRx IFRX|XFOR - Price to Earnings Ratio|ACET - Price to Earnings Ratio|Celularity Inc. (CELU) - Price to Earnings Ratio|INMB (INmune Bio Corp) - Price to Earnings Ratio|Barinthus Biotherapeutics Corp (BRNS) - P/E Multiple|Price to Earnings Ratio Kezar Life Sciences|Price to Earnings Multiple SABS (sabbiotherapeutics.com)|P/E Multiple AKTX|ENLV - Market Cap to Earnings|P/E Multiple QTTB (Q32 Bio)|P/E Multiple GeoVax Corp GOVX|Edesa Biotech, Inc. - P/E Multiple|Market Cap to Net Income IBIO|CARM: P/E Multiple|Market Cap to Net Income XTLB (XTL Biopharmaceuticals Ltd)|BOLT (Bolt Biotherapeutics Inc.) - P/E Multiple|HCW Biologics Inc (HCWB) - Business Payback Period|Price to Earnings Ratio Aptevo Therapeutics (APVO)|Price to Earnings Ratio AIM ImmunoTech, Inc. AIM|P/E Multiple ADTX (Aditxt, Inc.)|GRI Bio Inc (GRI) - Market Cap to Earnings|XORTX - P/E Multiple|HIND (Vyome Therapeutics) - Price to Earnings Multiple|REVB: P/E Multiple|indaptusrx.com (INDP) - P/E Multiple|SCNI (Scinai Immunotherapeutics Ltd.) - P/E Multiple|CalciMedica Corp - Market Cap to Net Income|Price to Earnings Ratio Allakos Inc. (ALLK)|Price to Earnings Ratio hookipapharma.com HOOK|P/E Multiple IGMS (IGM Biosciences)|ITOS: Price to Earnings Multiple|OCEA - Price to Earnings Ratio|Market Cap to Net Income TCBP|THRD: P/E Multiple